title: Therapy-activated stromal cells can dictate tumor fate.
abstract: In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis.
authors.affiliation: Sunnybrook Research Institute, University of Toronto, Toronto, Ontario M4N 3M5, Canada and Technion - Israel Institute of Technology, Haifa 3200003, Israel.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kerbel
authors.affiliation: Sunnybrook Research Institute, University of Toronto, Toronto, Ontario M4N 3M5, Canada and Technion - Israel Institute of Technology, Haifa 3200003, Israel.
authors.forename: Yuval
authors.initials: Y
authors.lastname: Shaked
mesh_terms: D000818:Animals; D006801:Humans; D059250:Administration, Metronomic; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D019707:Receptors, Chemokine / Q000378:metabolism; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology
chemical_list: D009363:Neoplasm Proteins; D019707:Receptors, Chemokine